Prana Biotechnology Limited (PBT)

Welcome to InvestSMART

You are currently viewing our site as a guest, which gives you limited access to our site features. By signing up for a free membership, you will receive our Investment Opportunity newsletters and have access to additional features for finding and comparing managed funds and shares. Registration is fast and simple, so please:

Sign Up Today » it's FREE! Already a member? Login now!

General Information
Company Name: Prana Biotechnology Limited
Stock Code: PBT
GICS Sub-Industry: Biotechnology
Market Cap ($M): 74
Equiv. Shares (M): 527

Current Price Data+
Current Price Open High Low Last Close Volume Price Movement
$ 0.140 $ 0.140 $ 0.140 $ 0.140 $ 0.140 241,745 0%

Company Overview

Business Description:
Prana Biotechnology Limited (PBT) is an Australian biotechnology company with a focus on the development of pharmaceutical products designed to treat the underlying causes of degeneration of the brain and the eye as the aging process progresses Potential applications for PBT’s MPAC (Metal-Protein Attenuating Compound) technology including Alzheimer’s, Parkinson’s and Huntington’s diseases and brain cancer.

Strategy Analysis:
The Company's focus is the development of the disease modifying therapeutics for the treatment of common neurological disorders, with a focus upon Alzheimer's, Parkinson's and Huntington's disease. Other potential applications for this platform technology include specific cancers and Age-related Macular Degeneration. Prana's lead compound PBT2 has completed Phase IIa clinical trial in patients with early Alzheimer's Disease. Planning is currently underway for a Phase IIb clinical trial of PBT2 in patients with mild to moderate Alzheimer's Disease. Prana is currently validating candidate leads from its MPAC library in the selection of PBT3 and PBT4 series compounds to be designated as follow ups of PBT2 in AD, or for use in secondary alternative indications..

Financial Summary
Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2014  A -13.3 -3.1 -- 0.0 0.0 0.0 --
2013  A -7.8 -2.3 -- 0.0 0.0 0.0 --
2012  A -5.2 -1.8 -- 0.0 0.0 0.0 --
Source: Aspect actuals / Thomson IBES estimates

Peer Comparison
EPS Growth (%) P/E (%) Dividend Yield (%)
Company Mkt Cap 2012 A 2013 F 2014 F 2012 A 2013 F 2014 F 2012 A 2013 F 2014 F
Bionomics (BNO) $203 M -- -- -- 62.9870 -- 4.9189 0.00 0.00 0.00
CSL (CSL) $43,105 M 0.0899 0.3357 0.0808 32.1000 24.0329 22.2368 1.31 1.74 1.98
Mesoblast (MSB) $1,161 M -- -- -- -- -- -- 0.00 0.00 0.00
Prana Biotech (PBT) $74 M -- -- -- -- -- -- 0.00 -- --
Sirtex Medical (SRX) $1,132 M 0.2906 0.6080 0.2576 48.4746 30.1461 23.9703 0.70 0.96 1.45

Market Comparison
Earnings P/E Ratio P/B Ratio P/E Growth P/S Ratio
PBT -- -- 1.82 -- --
Market 0.91 14.4 1.02 1.16 2.88
Sector 0.81 15.2 2.59 1.27 7.75

Name Position Start Date
Mr Geoffrey Paul Kempler Executive Director,Chief Executive Officer,Executive Chairman 11 November 1997
Mr Brian Derek Meltzer Non-Executive Director 09 December 1999
Dr George William Mihaly Non-Executive Director 09 December 1999
Mr Peter Marks Non-Executive Director 29 July 2005
Mr Lawrence Gozlan Non-Executive Director 08 August 2011
Professor Ira Shoulson Non-Executive Director 13 May 2014

Name Position
Phillip Hains Acting Chief Financial Officer
Dianne Angus Chief Operating Officer
Kathryn Andrews Company Secretary

Calendar of Events
Date Event
23 February 2016 Report (Interim)
03 November 2015 Report (Annual)
29 September 2015 Report (Annual)
28 August 2015 Report (Prelim)
© 2011 Morningstar, Inc. All rights reserved. The data and content contained herein are not guaranteed to be accurate, complete or timely. Neither Morningstar, nor its affiliates nor their content providers will have any liability for use or distribution of any of this information. To the extent that any of the content above constitutes advice, it is general advice that has been prepared by Morningstar Australasia Pty Ltd ABN: 95 090 665 544, AFSL: 240892 (a subsidiary of Morningstar, Inc.), without reference to your objectives, financial situation or needs. Before acting on any advice, you should consider the appropriateness of the advice and we recommend you obtain financial, legal and taxation advice before making any financial investment decision. If applicable investors should obtain the relevant product disclosure statement and consider it before making any decision to invest. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). DISCLOSURE: Employees may have an interest in the securities discussed in this report. Please refer to our Financial Services Guide (FSG) for more information at


Trade Shares Online from $19.95^
Free Guides

The SMH Guide to Trading Forex

An educational booklet with information on becoming a successful trader, including essentials you need to learn and the skills you need to develop.

More details...


Markets melt up

By Michael McCarthy (chief market strategist, CMC Markets) 19/12/2014 | Traders and investors caught short heading into the FOMC scrambled for cover in Europe and the US, in many cases driving indices to their best one day performance for 2015.

Aussie Investors take their foot off the accelerator

By Betty Lam (Sales Trader, CMC Markets) 18/12/2014 | Lead by the Fed-fervour offshore, Australians shares jumped on the Yellen cheer wagon. The material and energy stocks were back in vogue as both sectors gained over 3% in morning trade.

Fed Feeds Frenzy

By Michael McCarthy (chief market strategist, CMC Markets) 18/12/2014 | In spite of a frenzied pre-mortem, a benign statement from the US Federal Reserve’s Open Market Committee and steadying commodity markets drove investors back into share markets overnight. A calmer, stronger ruble helped offset European growth fears, highlighted in the overnight session by further declines in inflation.

Household brands Woolworths and Telstra Heavy Lifting

By Betty Lam (Sales Trader, CMC Markets) 11/12/2014 | Offshore jitters sent ripples through to Australian stocks. The open saw the local equities take 65 points off the index, catalysed by a mass-exit in energy stocks, yet again.

Steady open as Woodside investors wait on details of possible Wheatstone acquisition

By Ric Spooner (Chief Market Analyst, CMC Markets) 10/12/2014 | Yesterday’s news on Greek politics and China’s bond market came at a time when US and European stock markets have extended rallies and pushed valuations higher. This makes those markets vulnerable to downward corrections as profit takers act to avoid missing out.

MYEFO and Lima - December could be nasty.

BR Securities Australia Pty Ltd 2/12/2014 | December 2014 could go down as a nasty moment in Australian finance. MYEFO will reveal a deteriorating budget deficit and the UNFCCC meeting in Lima, Peru will provide the agreement, to be ratified in Paris in 2015, on how much (or little) CO2 is to be allowed into the atmosphere from 2020.


Sponsored Links